Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2011-07-05
2011-07-05
Meller, Michael V (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
07972632
ABSTRACT:
The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5443983 (1995-08-01), OChoa et al.
patent: 5589160 (1996-12-01), Rice
patent: 5643598 (1997-07-01), Meybeck
patent: 5650432 (1997-07-01), Walker
patent: 5650433 (1997-07-01), Watanabe et al.
patent: 5756538 (1998-05-01), Cassels et al.
patent: 5858371 (1999-01-01), Singh et al.
patent: 6083921 (2000-07-01), Xu
patent: 6217875 (2001-04-01), Murai et al.
patent: 6235294 (2001-05-01), Perrier et al.
patent: 6264995 (2001-07-01), Newmark et al.
patent: 6290995 (2001-09-01), Xinxian
patent: 6387416 (2002-05-01), Newmark et al.
patent: 6391346 (2002-05-01), Newmark et al.
patent: 6685971 (2004-02-01), Xu
patent: 2001/0026813 (2001-10-01), Kim et al.
patent: 2001/0046963 (2001-11-01), Wenzel et al.
patent: 2002/0086070 (2002-07-01), Kuhrts
patent: 2002/0122836 (2002-09-01), Obukowicz et al.
patent: 2002/0136784 (2002-09-01), Obukowicz et al.
patent: 2003/0105030 (2003-06-01), Liao et al.
patent: 2003/0166583 (2003-09-01), Yoa-Pu Hu et al.
patent: 2005/0049206 (2005-03-01), Gong et al.
patent: 2126513 (1995-01-01), None
patent: 1096680 (1994-12-01), None
patent: 1285202 (2001-02-01), None
patent: 0 633 022 (1994-06-01), None
patent: 0742012 (1996-11-01), None
patent: 2651132 (1991-03-01), None
patent: 2687572 (1992-02-01), None
patent: 61-083179 (1986-04-01), None
patent: S61-161219 (1986-07-01), None
patent: 405331061 (1993-12-01), None
patent: H07-025761 (1995-01-01), None
patent: 07223941 (1995-08-01), None
patent: H07277942 (1995-10-01), None
patent: H08-026969 (1996-01-01), None
patent: 8104628 (1996-04-01), None
patent: H10-182415 (1998-07-01), None
patent: H10-287528 (1998-10-01), None
patent: WO 00/59523 (2000-10-01), None
patent: WO 03/015766 (2003-02-01), None
Afolayan and Meyer (1997) Journal of Ethnopharmacol. 57(3):177-181, The antimicrobial activity 3,5,7-trihydroxyflavone isolated from the shoots ofHelichrysum aureonitens.
Ardlie et al. (1985) Thromb. Res. 38(6):695-706, Effects of Trifluoperazine of Platelet Activation.
Boumendjel et al. (2001) Bioorg. Med. Chem. Lett. 11(1):75-77, B-ring substituted 5,7 Dihydroxyflavonols with High-Affinity Binding to P-Glycoprotein Responsible for Cell Multidrug Resistance.
Brideau et al. (1996) Inflamm Res. 45:68-74, A Human Whole Blood Assay for Clinical Evaluation of Biochemical Efficacy of Cyclooxygenase Inhibitors.
Butenko et al., (Mar. 1993)Agents Actions39, Special Conference Issue C49-050, Anti-inflammatory properties and inhibition of leukotriene C4Biosynthesis in vitro by flavonoid baicalein fromScutellaria baicalensisgeorgy roots.
Chen et al. (2001) Biochem. Pharmacol. 61(11):1417-1427, Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide.
Chen et al. (Jun. 1, 2000) Biochemical Pharmacology 59(11):1445-1447, Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation.
Chi et al. (2001) Biochem. Pharmacol. 61:1195-1203, Effect of wogonin, a plant flavone fromScutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipopolysaccharide-treated RAW 264.7 cells.
Chung et al. (Apr. 1995) Planta Med.(NY)61:150-153, Pharmacological Effects of Methanolic Extract from the Root ofScutellaria baicalensisand its Flavonoids on Human Gingival Fibroblast.
Commenges et al. (Apr. 2000) Eur. J. Epidemiol 16:357-363, Intake of flavonoids and risk of dementia.
de la Puerta et al. (1999) Planta Medica 65:507-511, Inhibition of Leukocyte Eicosanoid Generation and Radical Scavenging Activity by Gna phalin, a Lipophilic Flavonol Isolated fromHelichrysum picardii.
de Whalley et al. (1990) Biochemical Pharmacology 39:1743-1750, Flavonoids Inhibit the Oxidative Modification of Low Density Lipoproteins by Macrophages.
Heo et al. (2001) Mutat. Res. 488(2):135-150, Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate.
Imamura et al. (2000) J. Biochem. 127(4):653-658, Inhibitory Effects of Flavonoids on Rabbit Heart Carbonyl Reductase.
Itoigawa et al. (1999) J. Ethnopharmacol. 65(3): 267-272, Structure-activity relationship of cardiotonic flavonoids in guinea-pig papillary muscle.
Kalkbrenner et al. (1992) Pharmacology 44(1):1-12, In vitro Inhibition and Stimulation of Purified Prostagladin Endoperoxide Synthase by Flavonoids: Structure-Activity Relationship.
Kaneko and Baba (1999) Biosci Biotechnol. Biochem 63(2):323-328, Protective Effect of Flavonoids on Endothelial Cells Against Linoleic Acid Hydroperoxide-induced Toxicity.
Kikukawa et al., (1995) Ensho 15(2):129-33, Mechanism of suppressive action of TJ114 upon murine type II collagen-induced arthritis (Abstract only).
Kim et al. (1990) Yakhak Hoeji 34(5):348-364, Pharmacological Activities of Flavonoids (I)—Relationships of Chemical Structure of Flavonoids and their Inhibitory Activity of Hypersensitivities.
Kimura et al. (2001) Planta Med. 67:331-334, Effects of Baicalein Isolated fromScutellaria baicalensisRadix on Adhesion Molecule Expression Induced by Thrombin and Thrombin Receptor Agonist Peptide in Cultured Human Umbilical Vein Endothelial Cells.
Krakauer et al. (2001) FEBS Lett. 500:52-55, The flavonoid baicalin inhibits superantigen-induced inflammatory cytokines and chemokines.
Kubo et al. (2000) Bioorg. Med. Chem. 8(7):1749-1755, Flavonols fromHeterotheca inuloides: Tyrosinase Inhibitory Activity and Structural Criteria.
Kubo et al., (1984) Chem. Pharm. Bull. 32(7):2724-2729, Studies on Scutellariae Radix. VII.1)Anti-arthritic and Anti-inflammatory Actions of Methanolic Extract and Flavonoid Components from Scutellariae Radix.
Li et al. (2000) Immunopharmacology 49:295-306, The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines.
Liang et al. (2001) FEBS Lett. 496(1):12-18, Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-γ by flavonoids in mouse macrophages.
Meyer et al. (1997) J. Ethnopharmacol. 56(2):165-169, Antiviral activity of galangin isolated from the aerial parts ofHelichrysum aureonitens.
Moroney et al. (1988) J. Pharm. Pharmacol. 40:787-792, Selectivity of Neutrophil 5-Lipoxygenase and Cyclo-oxygenase Inhibition by an Anti-inflammatory Flavonoid Glycoside and Related Aglycone Flavonoids.
Mutoh et al. (Jul. 2000) Jnp. J. Cancer Res. 91:686-691, Suppression by Flavonoids of Cyclooxygenase-2 Promoter-dependent Transcriptional Activity in Colon Cancer Cells: Structure-Activity Relationship.
Nakahata et al. (1998) Am. J. Chin Med. 26:311-323, Analysis of Inhibitory Effects of Scutellariae Radix and Baicalein on Prostaglandin E2 Production in Rat C6 Glimo Cells (abstract).
Nakahata et al. (1999) Nippon Yakurigaku Zasshi,114, Supp. 11:215P-219P, Mitogen-activated Protein Kinase.
Nakajima et al. (2001) Planta Med. 67(2):132-135, Inhibitory Effect of Baicalein, a Flavonoid inScutellariaRoot, on Eotaxin Production by Human Dermal Fibroblasts.
Nakagami (Aug. 22, 1995) abstract Database WPI Week 199519 Aug. 22, 1995, Derwent Publications Ltd., London, GB; p. 2, AN 1995-325471 XP002418722 “Anti-complementary substance used as therapeutic agent—comprises gallic acid, methyl gallate, acetyl-salicylic acid, caffeic acid, catechin, epi-gallo-catechin gallate, myricetin,
Meller Michael V
Seed IP Law Group PLLC
Unigen Pharmaceuticals, Inc.
LandOfFree
Identification of Free-B-Ring flavonoids as potent COX-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of Free-B-Ring flavonoids as potent COX-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of Free-B-Ring flavonoids as potent COX-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735689